Search

everythinglearnresearchcommunity

for

Search:↓

The potential availability of a new hair loss treatment called HMI-115, which has shown promising results in experiments on monkeys but is not yet available to the public. Replies cautioned against using unproven substances from shady labs.

PP405 is being discussed as a potential hair loss treatment, possibly more effective than minoxidil. There are concerns about its effectiveness and product contamination, but some users report early signs of hair regrowth.

The conversation discusses hair loss treatments, specifically the use of dutasteride, finasteride, and other methods like PRP, laser, and mesotherapy. Despite these treatments, the user is experiencing hair loss, and others suggest consulting a dermatologist, considering alternative treatments, and addressing potential scalp inflammation.

PP405 significantly improves hair density, outperforming finasteride, with 31% of users seeing over 20% improvement in four weeks. Concerns exist about its availability, cost, and long-term effects.

The post argues that Post-Finasteride Syndrome (PFS) is likely not real and suggests symptoms may be due to mental health issues or the nocebo effect. The conversation includes personal experiences with finasteride, highlighting both positive and negative effects, and emphasizes consulting doctors and using reliable sources for medication.

The conversation is about hair loss treatments. The user considers using a foam with Saw palmetto, caffeine, and EGCG, but another user suggests just using finasteride.

PP405 is discussed as a potential adjunct therapy for hair loss, with skepticism about its effectiveness and trial results. Users mention combining it with finasteride and minoxidil for better results, while others debate the root causes of hair loss and the limitations of current treatments.

Pelage Pharmaceuticals' PP405, a new hair loss treatment, was recognized by Time Magazine as one of the best inventions of 2025. The conversation expresses optimism about the recognition of this in-development treatment.

A Silicon Valley-backed company aims to cure hair loss. Exciting advancements include mRNA therapies, gene editing, hair cloning, AR degraders, anti-androgens, cell-based rejuvenation, and AI-based drug discovery, with hopes for FDA approval of GT20029 within 10 years.

Hair loss discussion includes PRP and exosomes treatments. Questioning effectiveness and ideal candidate for these treatments.

A user is considering trying Aevin hair creme, which contains ingredients like jojoba oil and saw palmetto, despite skepticism about its effectiveness compared to treatments like finasteride, minoxidil, or hair transplants. They are wary of the product's legitimacy due to the lack of reviews outside the brand's website.

The user is seeing slow hair regrowth using Minoxidil, Finasteride, a derma roller, vitamins, and zinc. Some suggest switching to dutasteride or adding other treatments, but others doubt significant cosmetic improvement due to advanced hair loss.

A 3-month update on a microneedling-only project to treat hair loss, which has not had significant results in terms of thicker hair but may have seen some acceleration in hair growth and an increase in vellus hairs. The user plans to continue the journey for 6 months before making any changes, such as adding minoxidil or finasteride.

The conversation is about a hair loss regimen using Veta hair products, 2% keto shampoo, 1% zinc shampoo, and 0.05% retin-a topical. The user seeks natural alternatives due to adverse effects from finasteride.

A new topical treatment, TH07, combining finasteride, latanoprost, and minoxidil, is entering phase III trials with promising early results. Some users express skepticism, noting the treatment uses existing products.

The conversation is about whether vellus hair should be included in hair fall counts, with data showing daily hair loss. The consensus is that shedding, including vellus hair, is normal and within physiological limits.

The conversation discusses the effectiveness of adding RCP (redensyl, capixyl, procapil) to a hair loss treatment regimen that includes minoxidil and finasteride. Users share experiences, suggesting RCP may not be as effective as minoxidil, but could be useful for creating topical solutions.

Concerns about France potentially banning finasteride and dutasteride due to supposed side effects, though no solid evidence supports this action. Users believe a ban is unlikely and discuss ways to obtain the treatments if it occurs.

A user's extreme regimen for hair loss, which includes taking oral and topical medications such as minoxidil, dutasteride, cyproterone acetate and bicalutamide, but still experiencing miniaturization. Suggestions were made to try other treatments such as RU58841 and Pyrilutamide, while also considering mental health treatment and advice on lookmaxxing.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

PP405 is a potential new hair loss treatment that might replace finasteride and minoxidil, but it is still in clinical trials and may not be available until 2028-2031. There is skepticism about its effectiveness, with only a 20% increase in hair density observed in some participants.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also mentions an update on Dr. Bloxham's Verteporfin treatment.

The user has been treating hair loss with finasteride, dutasteride, oral minoxidil, and pyrilutamide for several years without success and is experiencing an inflamed scalp, possibly due to seborrheic dermatitis. They are seeking advice on additional treatments after these methods failed to improve their condition.

The user has been using 1 mg finasteride for three months and recently started using 5% minoxidil once daily, resulting in new vellus hair growth. The user is hopeful that minoxidil will positively impact terminal hairs and is considering adding a derma stamp to the routine.

PP405 is a potential hair loss treatment showing promise, especially for men with severe balding. Some are hopeful it will be a game-changer for those who cannot tolerate finasteride or minoxidil, despite skepticism about the outcomes.

Automatic-Law-3612's progress with hair loss treatments, including topical finasteride, topical dutasteride, minoxidil and pyrilutamide. They have been using these products for two weeks and noticed baby hairs in their temples getting longer.

A user was frustrated with delays in getting finasteride for hair loss, was prescribed minoxidil, and found a vitamin B7 deficiency. They are questioning if the deficiency could cause receded temples and considering finding a new dermatologist.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

Topical Vitamin D3 may stimulate hair growth and has been used for Alopecia Areata. There is a question about the lack of research on its use for Androgenetic Alopecia (AGA).

The user successfully managed hair regrowth by using a combination of finasteride, dutasteride, minoxidil, and specific shampoos to treat seborrheic dermatitis. They emphasize the importance of maintaining a healthy scalp and are considering food intolerance tests to further address inflammation.